PARKINSON'S DISEASE (PD) GLOBAL CLINICAL TRIAL LANDSCAPE (2024)

#DYK Did you know?

2019: OVER 8.5M PD CASES

The Asia-Pacific region bears a high PD burden, with **China reporting over 3 million cases**

In North America, the **United States** reported higher PD cases

PARKINSON'S DISEASE (PD) IS THE

2nd

MOST COMMON NEURO-DEGENERATIVE DISORDER



In Europe, the PD incidence numbers show a considerable impact, with Germany, Russia, Italy, and France leading in the region, followed by ROW



The PD treatment market offers **diverse products** by companies including like **Abbott Laboratories, AbbVie Inc., Boston Scientific Corp, and InSightec Ltd.**

Ongoing trials across all stages are advancing PD treatment through **small molecules, proteins, cell, and stem cell therapies**, led by companies like **Amgen, BeiGene, Novo Nordisk, and Hope Biosciences**

Parkinson's Disease TRIAL CONTRIBUTIONS

Countries like **Mainland China**, **the United States**, **the United Kingdom**, **Japan**, **Russia**, **Spain**, **and Australia** emerged as top locations for conducting trials

Europe showed **faster recruitment durations** and **patient recruitment rates** 50% NORTH AMERICA & EUROPE

ASIA-PACIFIC

%

The content of this publication is proprietary to Novotech Health Holdings. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of Novotech except in the case of quotations embodied in reviews and non-commercial uses. Please note that this copyright statement applies specifically to this publication and its content and does not extend to other materials or intellectual property owned by Novotech. Any unauthorized reproduction or distribution of this publication or any portion thereof may result in legal action taken by Novotech to protect its rights. For permissions or inquiries, please contact: communications@novotech-cro.com